Merck acquires Prometheus Biosciences
Express Pharma
APRIL 17, 2023
Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialisation of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The acquisition is subject to Prometheus Biosciences shareholder approval.
Let's personalize your content